المؤلفون: Gossec, Laure, Baillet, Athan, Dadoun, Sabrina, Daien, Claire, Berenbaum, Francis, Dernis, Emmanuelle, Fayet, Françoise, Hudry, Christophe, Mezieres, Maryse, Pouplin, Sophie, Richez, Christophe, Saraux, Alain, Savel, Carine, Senbel, Eric, Soubrier, Martin, Sparsa, Laëtitia, Wendling, Daniel, Dougados, Maxime

المساهمون: Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Rhumatologie CHU de Grenoble, Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes 2016-2019 (UGA 2016-2019 ), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service de Rhumatologie CHU de Montpellier, CHU Montpellier, Centre de Recherche Saint-Antoine (UMRS893), Institut d'Imagerie BioMédicale (I2BM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Service de Rhumatologie CH Le Mans, Centre Hospitalier Le Mans (CH Le Mans), Service de Rhumatologie CHU Gabriel-Montpied, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de rhumatologie CHU Cochin, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Rhumatologie CHU Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Bordeaux (UB), Service de Rhumatologie CHU Pellegrin, Groupe hospitalier Pellegrin, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Service de Rhumatologie CHU de la Cavale-Blanche, Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Service de Rhumatologie CHU Sainte Marguerite, Hôpital Sainte-Marguerite CHU - APHM (Hôpitaux Sud ), Centre Hospitalier Emile Muller Mulhouse (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC), Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université Paris Descartes - Paris 5 (UPD5), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: ISSN: 1297-319X ; Joint Bone Spine ; https://hal.sorbonne-universite.fr/hal-01340133Test ; Joint Bone Spine, 2016, ⟨10.1016/j.jbspin.2016.05.012⟩.

مصطلحات موضوعية: Comorbidities, Rheumatoid arthritis, Spondyloarthritis, Management, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; IntroductionIn chronic inflammatory rheumatic diseases (CIRDs), comorbidities such as cardiovascular disease and infections are sub-optimally managed. EULAR recently developed points to consider to collect and report comorbidities. The objective of this present study was to develop a pragmatic guide to collect, report and propose management recommendations for comorbidities, from a rheumatologist perspective.MethodsThe collection and reporting of comorbidities and risk factors was adapted from the EULAR points to consider. To develop management recommendations, the process comprised (1) systematic literature reviews by 3 fellows and (2) a 2-day consensus process involving 110 experts (rheumatologists and health professionals). Votes of agreement (Likert 1-5 where 5 indicates full agreement) were obtained.ResultsThe six selected comorbidities were ischemic cardiovascular diseases, malignancies, infections, diverticulitis, osteoporosis and depression. The literature review retrieved 97 articles or websites, mostly developed for the general population. The consensus process led to reporting presence of comorbidities, current treatment, risk factors (e.g. hypertension), screening (e.g. mammography) and prevention (e.g. vaccination). Management recommendations include physical examination (e.g. blood pressure or lymph node examination), prescribing screening procedures, and interpreting results to refer in a timely manner to appropriate other health professionals. Agreement was high (mean ± standard deviation, 4.37 ± 0.33).ConclusionsUsing an evidence-based approach followed by expert consensus, this initiative furthers the dissemination in France of the EULAR points to consider, and clearly defines what part of the management of comorbidities is potentially within the remit of rheumatologists. This initiative should facilitate systematic management of patients with CIRDs.

العلاقة: hal-01340133; https://hal.sorbonne-universite.fr/hal-01340133Test; https://hal.sorbonne-universite.fr/hal-01340133/documentTest; https://hal.sorbonne-universite.fr/hal-01340133/file/Gossec%20et%20al_Collection%20and.pdfTest

الإتاحة: https://doi.org/10.1016/j.jbspin.2016.05.012Test
https://hal.sorbonne-universite.fr/hal-01340133Test
https://hal.sorbonne-universite.fr/hal-01340133/documentTest
https://hal.sorbonne-universite.fr/hal-01340133/file/Gossec%20et%20al_Collection%20and.pdfTest

المؤلفون: Lohse, A., Lemelle, I., Pillet, P., Duquesne, A., Ballot, C., Tran, TA., Sparsa, L., Goumy, L., Reumaux, H., Rossi-Semerano, L., Solau-Gervais, E., Anaïs, A., Alleyrat, C., Guillemin, Francis, Devauchelle-Pensec, V

المساهمون: Service d'Epidémiologie et Evaluations Cliniques CHRU Nancy (Pôle S2R), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)

المصدر: 31ème Congrès Français de Rhumatologie
https://hal.univ-lorraine.fr/hal-01997885Test
31ème Congrès Français de Rhumatologie, Dec 2018, Paris, France. pp.A121

مصطلحات موضوعية: Arthrite juvénile idiopathique, Adolescents, Enfants, Observancance thérapeuthique, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

جغرافية الموضوع: Paris, France

الوصف: National audience

العلاقة: hal-01997885; https://hal.univ-lorraine.fr/hal-01997885Test

الإتاحة: https://hal.univ-lorraine.fr/hal-01997885Test

المؤلفون: Françoise Fayet, Carine Savel, Martin Soubrier, Eric Senbel, Athan Baillet, Emmanuelle Dernis, Maryse Mezieres, Claire Daien, Francis Berenbaum, Maxime Dougados, Laure Gossec, Christophe Hudry, Daniel Wendling, L Sparsa, Sophie Pouplin, Sabrina Dadoun, Christophe Richez, Alain Saraux

المساهمون: Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Rhumatologie [CHU de Grenoble], Hôpital Sud de Grenoble, Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), Centre National de la Recherche Scientifique (CNRS)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Service de Rhumatologie [CHU de Montpellier], CHU Montpellier, Centre de Recherche Saint-Antoine (UMRS893), Institut d'Imagerie BioMédicale (I2BM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Service de Rhumatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Rhumatologie [CHU Gabriel-Montpied], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de rhumatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Bordeaux (UB), Service de Rhumatologie [CHU Pellegrin], Groupe hospitalier Pellegrin, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Service de Rhumatologie [CHU de la Cavale-Blanche], Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Service de Rhumatologie [CHU Sainte Marguerite], Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université Paris Descartes - Paris 5 (UPD5), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Groupe de Recherche et d'Etudes du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF), CHU Saint-Antoine [APHP], Service de Rhumatologie [CHU Le Mans], CHU Le MAns, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Plateforme nouvelles technologies, Hôpital Universitaire Raymond-Poincaré, Service de Rhumatologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Service de rhumatologie [Rouen], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Groupe de Recherche et d'Etudes du Processus Inflammatoire ( GREPI ), Université Joseph Fourier - Grenoble 1 ( UJF ), Institut de Génétique Moléculaire de Montpellier ( IGMM ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ), Dpt Rhumatologie [CHU St-Antoine], Service de Rhumatologie [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Université de Bordeaux ( UB ), Hôpital de la Cavale Blanche - CHRU Brest ( CHU - BREST ), Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, Hôpital Sainte-Marguerite [CHU - APHM] ( Hôpitaux Sud ), Centre Hospitalier Emile Muller [Mulhouse] ( CH E.Muller Mulhouse ), Groupe Hospitalier de Territoire Haute Alsace ( GHTHA ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), Université de Franche-Comté ( UFC ), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ), CHU Pitié-Salpêtrière [AP-HP], VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Institut d'Imagerie BioMédicale ( I2BM ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Rouen

المصدر: Joint Bone Spine
Joint Bone Spine, Elsevier Masson, 2016, ⟨10.1016/j.jbspin.2016.05.012⟩
Joint Bone Spine, Elsevier Masson, 2016
Joint Bone Spine, 2016, ⟨10.1016/j.jbspin.2016.05.012⟩
Joint Bone Spine, Elsevier Masson, 2016, 〈10.1016/j.jbspin.2016.05.012〉

مصطلحات موضوعية: medicine.medical_specialty, Consensus, Population, Alternative medicine, Physical examination, Comorbidity, Disease, Likert scale, Comorbidities, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Rheumatic Diseases, Spondyloarthritis, medicine, Humans, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, 030212 general & internal medicine, Rheumatoid arthritis, education, Screening procedures, Depression (differential diagnoses), 030203 arthritis & rheumatology, education.field_of_study, medicine.diagnostic_test, business.industry, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Diverticulitis, medicine.disease, 3. Good health, Management, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Family medicine, Chronic Disease, Practice Guidelines as Topic, Physical therapy, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business

الوصف: International audience; IntroductionIn chronic inflammatory rheumatic diseases (CIRDs), comorbidities such as cardiovascular disease and infections are sub-optimally managed. EULAR recently developed points to consider to collect and report comorbidities. The objective of this present study was to develop a pragmatic guide to collect, report and propose management recommendations for comorbidities, from a rheumatologist perspective.MethodsThe collection and reporting of comorbidities and risk factors was adapted from the EULAR points to consider. To develop management recommendations, the process comprised (1) systematic literature reviews by 3 fellows and (2) a 2-day consensus process involving 110 experts (rheumatologists and health professionals). Votes of agreement (Likert 1-5 where 5 indicates full agreement) were obtained.ResultsThe six selected comorbidities were ischemic cardiovascular diseases, malignancies, infections, diverticulitis, osteoporosis and depression. The literature review retrieved 97 articles or websites, mostly developed for the general population. The consensus process led to reporting presence of comorbidities, current treatment, risk factors (e.g. hypertension), screening (e.g. mammography) and prevention (e.g. vaccination). Management recommendations include physical examination (e.g. blood pressure or lymph node examination), prescribing screening procedures, and interpreting results to refer in a timely manner to appropriate other health professionals. Agreement was high (mean ± standard deviation, 4.37 ± 0.33).ConclusionsUsing an evidence-based approach followed by expert consensus, this initiative furthers the dissemination in France of the EULAR points to consider, and clearly defines what part of the management of comorbidities is potentially within the remit of rheumatologists. This initiative should facilitate systematic management of patients with CIRDs.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f6fb4d109681eb4e47799f831b7cabTest
https://hal.sorbonne-universite.fr/hal-01340133Test

المؤلفون: Sparsa, Agnès, Blaise, Sophie, Tack, Brigitte, Dalmay, François, Leroy, Dominique, Bonnetblanc, Jean-Marie, Béani, Jean-Claude, Bédane, Christophe

المساهمون: Service de Dermatologie CHU Limoges, CHU Limoges, Service de Biochimie et Génétique Moléculaire CHU Limoges, Homéostasie Cellulaire et Pathologies (HCP), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges (UNILIM), Département Pluridisciplinaire de Médecine, Dermatologie, Centre Hospitalier Universitaire CHU Grenoble (CHUGA)-Hôpital Michallon

المصدر: ISSN: 0031-8655.

مصطلحات موضوعية: MESH: Adult, MESH: Aminolevulinic Acid, MESH: Photochemotherapy, MESH: Photosensitizing Agents, MESH: Prospective Studies, MESH: Treatment Outcome, MESH: Warts, MESH: Female, MESH: Hand, MESH: Humans, MESH: Immunocompromised Host, MESH: Kidney Transplantation, MESH: Light, MESH: Male, MESH: Middle Aged, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; Many studies have been conducted showing that aminolevulinic acid (ALA)-photodynamic therapy (PDT) can be an alternative treatment for recalcitrant warts. Recently, we performed a study evaluating methyl-aminolevulinic acid (MAL)-PDT for the treatment of hand warts in a population of renal transplant patients. Two symmetrical targets were selected on each hand and randomly assigned to chemical keratolytic treatment followed by three cycles of ALA-PDT (75 J cm(-2) red light). Patients were evaluated after 3 months and a second run of PDT was performed if the total area and number of warts decreased less than 50%, with evaluation every 3 months for 1 year. Twenty patients were included and 16 were evaluable (9 M, 7 F). After 6 months the reduction of warts' area was 48.4% on the treated side versus 18.4% in the control area (P = 0.021). The decrease in the total number of warts was 41%versus 19.4% (P = NS). The global tolerance of the treatment was good with acceptable pain during irradiation. These results suggest that ALA-PDT is a safe and efficient treatment for transplanted patient warts. The improvement between treated and control zone is 20% due to the decrease in untreated warts' area and number.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/22332671; hal-00933565; https://unilim.hal.science/hal-00933565Test; PUBMED: 22332671

الإتاحة: https://doi.org/10.1111/j.1751-1097.2012.01114.xTest
https://unilim.hal.science/hal-00933565Test

المؤلفون: Dominique Leroy, Christophe Bedane, Jean-Marie Bonnetblanc, Jean-Claude Béani, Sophie Blaise, Brigitte Tack, François Dalmay, Agnès Sparsa

المساهمون: Service de Dermatologie [CHU Limoges], CHU Limoges, Service de Biochimie et Génétique Moléculaire [CHU Limoges], Homéostasie Cellulaire et Pathologies (HCP), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Hypoxie et physiopathologies cardiovasculaire et respiratoire, Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges (UNILIM), Département Pluridisciplinaire de Médecine, Dermatologie, CHU Grenoble-Hôpital Michallon

المصدر: Photochemistry and Photobiology
Photochemistry and Photobiology, Wiley, 2012, 88 (4), pp.1023-6. ⟨10.1111/j.1751-1097.2012.01114.x⟩

مصطلحات موضوعية: Male, Light, medicine.medical_treatment, Keratolytic, MESH: Photosensitizing Agents, Photodynamic therapy, Biochemistry, law.invention, MESH: Kidney Transplantation, 030207 dermatology & venereal diseases, 0302 clinical medicine, Randomized controlled trial, law, MESH: Immunocompromised Host, Medicine, Prospective Studies, Red light, Prospective cohort study, MESH: Treatment Outcome, education.field_of_study, Photosensitizing Agents, MESH: Middle Aged, virus diseases, General Medicine, Middle Aged, 3. Good health, Treatment Outcome, Renal transplant, 030220 oncology & carcinogenesis, Female, Warts, Adult, medicine.medical_specialty, Population, MESH: Hand, Immunocompromised Host, 03 medical and health sciences, Humans, Physical and Theoretical Chemistry, education, MESH: Photochemotherapy, MESH: Humans, business.industry, MESH: Warts, MESH: Adult, Aminolevulinic Acid, Hand, Kidney Transplantation, MESH: Prospective Studies, MESH: Light, MESH: Male, Surgery, MESH: Aminolevulinic Acid, Photochemotherapy, Multicenter study, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female

الوصف: International audience; Many studies have been conducted showing that aminolevulinic acid (ALA)-photodynamic therapy (PDT) can be an alternative treatment for recalcitrant warts. Recently, we performed a study evaluating methyl-aminolevulinic acid (MAL)-PDT for the treatment of hand warts in a population of renal transplant patients. Two symmetrical targets were selected on each hand and randomly assigned to chemical keratolytic treatment followed by three cycles of ALA-PDT (75 J cm(-2) red light). Patients were evaluated after 3 months and a second run of PDT was performed if the total area and number of warts decreased less than 50%, with evaluation every 3 months for 1 year. Twenty patients were included and 16 were evaluable (9 M, 7 F). After 6 months the reduction of warts' area was 48.4% on the treated side versus 18.4% in the control area (P = 0.021). The decrease in the total number of warts was 41%versus 19.4% (P = NS). The global tolerance of the treatment was good with acceptable pain during irradiation. These results suggest that ALA-PDT is a safe and efficient treatment for transplanted patient warts. The improvement between treated and control zone is 20% due to the decrease in untreated warts' area and number.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9fb5e23fb9ef44619a4c9f84c1857f5Test
https://hal-unilim.archives-ouvertes.fr/hal-00933565Test